The same nine-year study found that patients using SGLT2 inhibitors had a 43% lower risk of dementia compared to those on other treatments.

Alzheimer's disease and type 2 diabetes share a key mechanism where cells lose the ability to respond properly to insulin, which regulates blood sugar.

A recent analysis projects that up to 42% of Americans over the age of 55 will eventually develop dementia, a much higher estimate than previously thought.

A recent nine-year study of patients with type 2 diabetes found that those taking a GLP-1 agonist had a 33% lower risk of developing dementia.

GLP-1 agonists like Ozempic can cross the blood-brain barrier to directly provide an anti-inflammatory effect and combat oxidative stress within the brain.

Large clinical trials called Evoke and Evoke plus are currently testing semaglutide on people with early-stage Alzheimer's, with results expected in 2026.

SGLT2 inhibitors work by blocking the kidneys from reabsorbing glucose, causing excess sugar to be filtered out and removed from the body through urine.